Targeting the JNK-JUN pathway to overcome therapy resistance in melanoma

靶向 JNK-JUN 通路克服黑色素瘤的治疗耐药性

• 批准号: nhmrc : 1126048
• 负责人: Dr Andreas Behren
• 金额: $ 47.48万
• 依托单位: La Trobe University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2017
• 资助国家: 澳大利亚
• 起止时间: 2017-01-01 至 2020-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/targeting-jnk-jun-resistance-melanoma/947716
• 关键词: Targeting; JNK; JUN; pathway; overcome

Melanoma patients can display remarkable responses to targeted and immunotherapies. However most patients progress rapidly on targeted therapies and only a small proportion respond to immunotherapies. We have found that combination treatment with JNK inhibitors can overcome therapy resistance. We will determine the most efficacious JNK inhibitors available, and the optimal dosing and scheduling of combination treatment for evaluation in patients to improve responses, outcomes and survival.

黑色素瘤患者可以对靶向治疗和免疫治疗表现出显着的反应。然而，大多数患者在靶向治疗方面进展迅速，只有一小部分患者对免疫治疗有反应。我们发现与JNK抑制剂联合治疗可以克服治疗耐药性。我们将确定最有效的JNK抑制剂，以及联合治疗的最佳剂量和时间表，以评估患者的反应，结果和生存率。